NNVC — NanoViricides, Share News
0.000.00%
Last trade - 00:00Brief: anoViricides Signs Agreement for Orphan Drug Strategy of NV-387 for Mpox, Smallpox, and Measles
Brief: Nanoviricides Says NV-387 Shows Activity Against Measles Virus In Humanized Animal Model
Brief: Nanoviricides Co's Business Not Affected By Tariff Policies Of Us Government Or Corresponding Retaliatory Policies Of Other Governments
Brief: Nanoviricides Obtained Right Of First Refusal For All Antiviral Drug Developments
Brief: Nanoviricides Investigating Possibility Of Using NV-387 For Treatment Of Mpox
Brief: Nanoviricides Plans On Exploring Effectiveness Of NV-387 For Treatment Of Severe Acute Respiratory Infections Caused By Viruses
Brief: NanoViricides Says NV-387 Effective In Protecting Lungs From Damage In Lethally Infected Animal Model
Brief: Nanoviricides Ultra-Broad Antiviral Activity Spectrum Of NV-387 Includes Activity Against Orthopoxvirus Family (Smallpox/Mpox)
Brief: Nanoviricides Files Prospectus Supplement Related To Issuance, Sale Of Up To $5.7 Mln Common Stock
RCS - NanoViricides, Inc. - NanoViricides: Clinical Trials, Antiviral NV-CoV-2
Brief: Nanoviricides Inc Files For Mixed Shelf Of Up To $150 Million – SEC Filing
Brief: Nanoviricides Inc - On March 27, Co Entered Into License Agreement With Karveer Meditech Private Limited
U.S. STOCKS ON THE MOVE-Global Blood, Alibaba.com, Albemarle
NanoViricides pulls back after prior session surge
AMEX RESUMED NANOVIRICIDES
AMEX HALT ADDITIONAL INFORMATION LAST 6.890000
AMEX RESUMED NANOVIRICIDES
AMEX HALT ADDITIONAL INFORMATION LAST 5.450000
AMEX RESUMED NANOVIRICIDES